8-K: bioAffinity Technologies Reports Record CyPath Lung Sales

bioAffinity Technologies announced record monthly unit sales for its CyPath Lung diagnostic test in April 2026, with a nearly 300% increase compared to the previous year.

Summary

• bioAffinity Technologies reported a record high in monthly unit sales for its CyPath Lung diagnostic test in April 2026.
• Preliminary unaudited data shows unit sales increased by nearly 300% in April 2026 compared to April 2025.
• This growth continues the trend of accelerating adoption and clinical use observed in the first quarter of 2026.
• The company attributes the growth to increased physician adoption and expanding clinical use of the noninvasive test.
• CyPath Lung aims to aid in diagnosing lung cancer and managing pulmonary nodules.
• The test utilizes flow cytometry and AI technology, incorporating a fluorescent porphyrin.
• In a clinical trial, CyPath Lung demonstrated 92% sensitivity and 87% specificity for detecting lung cancer in high-risk patients with small indeterminate nodules.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strongly positive development due to record sales, significant year-over-year growth, and exceeding internal projections, indicating strong market traction for their core product.

Positives

• Record high monthly unit sales for CyPath Lung in April 2026.
• Nearly 300% year-over-year increase in unit sales for April 2026 compared to April 2025.
• Accelerating physician adoption and expanding clinical use of the CyPath Lung test.
• Strong performance exceeding internal projections for the first quarter of 2026.
• High Negative Predictive Value (NPV) of 99% in a clinical trial, potentially sparing patients unnecessary invasive procedures.
• Demonstrated 92% sensitivity and 87% specificity in detecting lung cancer in high-risk patients.

Negatives

• The company is dependent on a single commercial product (CyPath Lung).
• Risks related to the regulatory environment for laboratory developed tests (LDTs).
• Uncertainty regarding the company's ability to obtain adequate reimbursement coverage for CyPath Lung.

Risks

• The company's ability to maintain and grow CyPath Lung unit volume.
• The company's ability to achieve or maintain profitability.
• Risks related to the regulatory environment for laboratory developed tests.
• The company's ability to obtain adequate reimbursement coverage for CyPath Lung.
• The company's ability to successfully execute its commercial strategy and expand its customer base.
• The outcome of ongoing and future clinical studies.

Future Outlook

The company is advancing initiatives to expand the clinical impact of its technology, including a large-scale longitudinal clinical study for CyPath Lung validation, broader use for monitoring lung cancer survivors, and R&D for diagnostic tests for asthma and COPD.

Management Comments

• "The growth in CyPath Lung usage continues to accelerate at a rapid pace as the value of our novel lung cancer diagnostic is increasingly being recognized."
• "CyPath Lung addresses a significant gap in the diagnostic pathway by supporting lung cancer risk stratification and pulmonary nodule management as physicians seek more accurate, noninvasive tools to assess cancer risk and detect disease at its earliest, most treatable stage."
• "We are very pleased with the unit growth that we delivered in April, and we remain focused on expanding adoption of CyPath Lung to aid physicians in the early detection of lung cancer and pulmonary nodule management."

Industry Context

StockSavvy.ai notes that the strong performance of bioAffinity Technologies' CyPath Lung test aligns with the broader industry trend towards noninvasive diagnostics and early cancer detection, particularly in oncology. The increasing focus on AI and advanced flow cytometry in diagnostic tools reflects a significant shift in how complex diseases are being identified and managed.

Stakeholder Impact

• Shareholders may see positive impact from strong sales growth and exceeding internal projections.
• Physicians are provided with a tool to aid in lung cancer risk stratification and nodule management.
• Patients may benefit from earlier detection of lung cancer and potentially avoid unnecessary invasive procedures due to the test's high NPV.

Next Steps

• Continue to expand adoption of CyPath Lung.
• Execute a focused commercial strategy to accelerate adoption and scale.
• Advance initiatives to further expand the clinical impact of the proprietary technology platform.
• Conduct a large-scale longitudinal clinical study to generate additional validation data for CyPath Lung.
• Explore broader use of CyPath Lung to monitor lung cancer survivors after treatment.
• Develop diagnostic tests for asthma and COPD.

Key Dates

Recommendation

While the sales growth is exceptionally strong and positive, the company remains dependent on a single product, faces regulatory and reimbursement risks, and has not yet demonstrated consistent profitability. The positive momentum warrants a 'hold' to observe continued execution and progress on future initiatives.

Keywords

CyPath Lung, bioAffinity Technologies, lung cancer, diagnostic test, early detection, pulmonary nodules, biotechnology, flow cytometry